Skip to Main Content

In another effort to widen access to medicines, European consumer groups are urging the European Council to investigate four drug makers — including Roche and Gilead Sciences — for alleged anticompetitive practices.

In each instance cited by the consumer groups, the companies employed different tactics, such as halting supplies of several medicines as a negotiating tactic to boost prices, working with a rival to keep one of two medicines off the market, and imposing a high price for a key medicine when no competition existed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.